Triple agonists are a class of synthetic peptides engineered to activate three distinct G-protein-coupled receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
Calcineurin inhibitors promote cardiac hypertrophy, hypertension, dyslipidemia, and vascular remodeling, while mTOR inhibitors have an anti-proliferative effect with attenuation of cardiac hypertrophy and vascular remodeling despite promoting dyslipidemia
References Warburg, O
According to the NIH, several drugs have the potential to interact with L-carnitine
What evidence supports GHRP-2 in humans
In the general obesity population, cost-effectiveness is highly sensitive to drug price, treatment duration, and reimbursement context, and published models have reached variable conclusions (201203)